Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-741626
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Subcutaneous
01
Overview
L-741626 is a potent and selective antagonist for the dopamine receptor D₂. It has good selectivity over the related D₃ and D₄ subtypes. It is used primarily in laboratory research to study the roles of D₂ receptors in the brain and has been explored for its effects on various diseases, including cancer (hepatocellular carcinoma) by acting on pathways like the MAPK/ERK signaling pathway via non-dopamine receptor targets.
- Other names
- L741626L-741626L 741626
02
Targets
DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on L-741626.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L-741626.